Bristol-Myers Squibb BMY Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total Revenues by Product | |||||
| Abraxane | $368M-57.9% | $875M-12.8% | $1B+23.8% | $811M-31.3% | |
| Breyanzi | $1.36B+81.8% | $747M+105% | $364M+100% | $182M+109% | |
| Camzyos | $1.07B+77.6% | $602M+161% | $231M+863% | $24M— | |
| Cobenfy | $155M+1,450% | $10M— | $0— | $0— | |
| Eliquis | $14.44B+8.3% | $13.33B+9.2% | $12.21B+3.5% | $11.79B+9.5% | |
| Krazati | $205M+62.7% | $126M— | $0— | $0— | |
| Opdivo Qvantig | $239M— | $0— | $0— | —— | |
| Opdivo | $10.05B+8.0% | $9.3B+3.3% | $9.01B+9.2% | $8.25B+9.7% | |
| Opdualag | $1.19B+27.7% | $928M+48.0% | $627M+149% | $252M— | |
| Orencia | $3.71B+0.6% | $3.68B+2.2% | $3.6B+4.0% | $3.46B+4.8% | |
| Other Growth products | $2.03B+23.4% | $1.64B+35.6% | $1.21B+11.0% | $1.09B— | |
| Other Legacy products | $798M-13.7% | $925M-3.8% | $962M-17.2% | $1.16B— | |
| Pomalyst/Imnovid | $2.73B-22.9% | $3.55B+3.0% | $3.44B-1.6% | $3.5B+5.0% | |
| Reblozyl | $2.33B+31.2% | $1.77B+75.9% | $1.01B+40.6% | $717M+30.1% | |
| Revlimid | $2.95B-48.9% | $5.77B-5.3% | $6.1B-38.9% | $9.98B-22.2% | |
| Sotyktu | $290M+17.9% | $246M+44.7% | $170M+2,025% | $8M— | |
| Sprycel | $494M-61.6% | $1.29B-33.4% | $1.93B-10.9% | $2.17B+2.3% | |
| Yervoy | $2.9B+14.7% | $2.53B+13.0% | $2.24B+5.0% | $2.13B+5.2% | |
| Zeposia | $577M+1.9% | $566M+30.4% | $434M+73.6% | $250M+86.6% | |
| Total Revenues by Geography | |||||
| International | $13.83B+4.8% | $13.2B+0.8% | $13.1B-5.3% | $13.83B-15.3% | |
| Other | $1.09B+9.1% | $996M+42.5% | $699M-16.2% | $834M-2.1% | |
| United States | $33.28B-2.4% | $34.11B+9.3% | $31.21B-0.9% | $31.5B+7.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bristol-Myers Squibb break its business down?
- Bristol-Myers Squibb (BMY) reports total revenues by product across 20 parts — Abraxane, Breyanzi, Camzyos, Cobenfy and Eliquis. Each is extracted from the segment footnotes and tracked over time.
- Where does Bristol-Myers Squibb's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bristol-Myers Squibb's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
